Additional studies suggest that CCT3-LINC00326, a type of RNA-binding protein, interferes with the CCT3-LINC00326 network, reducing lipid accumulation, increasing lipid degradation, and decreasing tumor growth both in vivo and in vitro.[72] In summary, CCT3 is involved in HCC progression and serves as a potential biomarker and therapeutic target. Here, LINC00326 is linked to neoplasm.